The individualized treatment plan: A model for standardizing patient-centered cancer care—The experience of Medisprof Cancer Center.
Abstract
571 Background: Medisprof Cancer Center in Cluj-Napoca has implemented an Individualized Treatment Plan (ITP) as a practice recognized as ASCO Certified while participating in the International Pilot, becoming the only institution in Romania to use this tool systematically. In current national practice, structured documentation of therapeutic decisions at treatment initiation or line change is not a standard requirement, making this initiative a reference model for international quality standards. The ITP is developed by the treating oncologist or radiation oncologist and formalizes the therapeutic objectives, the multidisciplinary tumor board decision, and the coordination of the involved specialties. Methods: A retrospective observational study conducted over the period March 2025 – April 2026. All treatment plans completed at the center were analyzed, totaling 1,159. Each ITP includes: the oncologic diagnosis (ICD-10, TNM staging or equivalent classification), the treatment intent (curative / disease control / palliative), the recommended therapeutic modalities (surgery, radiotherapy, chemotherapy, hormone therapy, immunotherapy, targeted therapy), the medical specialties involved, and the scheduling of reassessment. Tumor sites, treatment intent, multidisciplinary involvement, and treatment modalities were assessed. Results: The most common tumor sites were: breast and colorectal cancer (19.8% each) and lung (12.1%). Treatment intent was curative in 57.0% of cases, disease control in 24.1%, and palliative in 15.2%. A multidisciplinary approach involving at least two specialties was documented in 54.6% of plans. Systemic therapy was recommended in 83.8% of cases: chemotherapy in 69.2% (first line — 36.8%, second line — 8.6%, third line or beyond — 10.8%), targeted therapy in 22.0%, hormone therapy in 18.6%, immunotherapy in 14.0%, and radiotherapy in 19.5%. Enrollment in clinical trials was documented in 0.9% of plans. Conclusions: The implementation of the Individualized Treatment Plan, within the framework of ASCO Certified program, has ensured the standardization of therapeutic decision documentation at Medisprof Cancer Center. The data confirm the applicability of the ITP across a broad oncologic spectrum and support its adoption as a national quality standard. A patient satisfaction survey is currently underway, aimed at evaluating the impact of the ITP on quality of care, administered to all patients who have received this tool. One identified challenge is the additional documentation time required from oncologists and radiation oncologists for ITP completion, representing an important consideration in terms of resource allocation. To address this, the center has initiated the implementation of AI-powered voice dictation software to streamline workflows and reduce physician workload.